Western University

Scholarship@Western
Paediatrics Publications

Paediatrics Department

12-1-2017

Variable phenotype expression in a family segregating
microdeletions of the NRXN1 and MBD5 autism spectrum
disorder susceptibility genes
Marc Woodbury-Smith
McMaster University

Rob Nicolson
Western University, rnicolso@uwo.ca

Mehdi Zarrei
The Centre for Applied Genomics University of Toronto

Ryan K.C. Yuen
The Centre for Applied Genomics University of Toronto

Susan Walker
The Centre for Applied Genomics University of Toronto

See next page for additional authors

Follow this and additional works at: https://ir.lib.uwo.ca/paedpub

Citation of this paper:
Woodbury-Smith, Marc; Nicolson, Rob; Zarrei, Mehdi; Yuen, Ryan K.C.; Walker, Susan; Howe, Jennifer;
Uddin, Mohammed; and Hoang, Ny, "Variable phenotype expression in a family segregating
microdeletions of the NRXN1 and MBD5 autism spectrum disorder susceptibility genes" (2017).
Paediatrics Publications. 2711.
https://ir.lib.uwo.ca/paedpub/2711

Authors
Marc Woodbury-Smith, Rob Nicolson, Mehdi Zarrei, Ryan K.C. Yuen, Susan Walker, Jennifer Howe,
Mohammed Uddin, and Ny Hoang

This article is available at Scholarship@Western: https://ir.lib.uwo.ca/paedpub/2711

www.nature.com/npjgenmed

CASE REPORT

OPEN

Variable phenotype expression in a family segregating
microdeletions of the NRXN1 and MBD5 autism spectrum
disorder susceptibility genes
Marc Woodbury-Smith1,2, Rob Nicolson3, Mehdi Zarrei2, Ryan K. C. Yuen 2, Susan Walker2, Jennifer Howe2, Mohammed Uddin4,
Ny Hoang5, Janet A. Buchanan2, Christina Chrysler1, Ann Thompson1, Peter Szatmari6 and Stephen W. Scherer2,7
Autism spectrum disorder is a developmental condition of early childhood onset, which impacts socio-communicative functioning
and is principally genetic in etiology. Currently, more than 50 genomic loci are deemed to be associated with susceptibility to
autism spectrum disorder, showing de novo and inherited unbalanced copy number variants and smaller insertions and deletions
(indels), more complex structural variants, as well as single-nucleotide variants deemed of pathological signiﬁcance. However, the
phenotypes associated with many of these genes are variable, and penetrance is largely unelaborated in clinical descriptions. This
case report describes a family harboring two copy number variant microdeletions, which affect regions of NRXN1 and MBD5—each
well-established in association with risk of autism spectrum disorder and other neurodevelopmental disorders. Although each copy
number variant would likely be categorized as pathologically signiﬁcant, both genomic alterations are transmitted in this family
from an unaffected father to the proband, and shared by an unaffected sibling. This family case illustrates the importance of
recognizing that phenotype can vary among exon overlapping variants of the same gene, and the need to evaluate penetrance of
such variants in order to properly inform on risks.
npj Genomic Medicine (2017)2:17 ; doi:10.1038/s41525-017-0020-9

INTRODUCTION
Autism spectrum disorder (ASD) is a developmental disorder of
early childhood onset that impacts socio-communicative functioning, and which is principally genetic in etiology.1 It has a high rate
of comorbidity with intellectual disability (ID) and other neurodevelopmental, neuropsychiatric, and medical disorders.1 ASD is
relatively common, affecting ~1.5% of children,2 and is often
associated with lifelong disability. Its core impairments and comorbidities present a major challenge for caregivers and
signiﬁcant demands on health-care provision, and, by implication,
health-care budget.3 Progress in elucidating its genetic etiopathogenesis will likely pave the way for new treatment options. To this
end, signiﬁcant progress has been made in the last decade with
the advent of dense, high-throughput genotyping. More than 50
genes and loci harbouring de novo and inherited copy number
variants (CNVs), structural variations, and single-nucleotide variants with diagnostic value (hereafter collectively referred to as
‘‘mutations’’ affecting the individuals discussed) have been
implicated in ASD so far.4, 5 Functionally, many of these genes
cluster in the post-synaptic density, whereas others are involved in
neurite growth or histone modiﬁcation.6
The term penetrance is used to describe the probability of a
particular speciﬁed phenotype or set of phenotypes in those
individuals harboring a particular mutation, whereas variable
expression describes the range of phenotypic features observed

among those with penetrant mutations.7 While some mutations
are strongly associated with neurodevelopmental phenotypes
such as intellectual disability and/or ASD,8 many of the mutations
in the identiﬁed genes are characterized by incomplete penetrance, and variable expressivity and pleiotropy are seen in
association with particular genotypes.9 For example, CNVs at
16p11–13 have been described in association with ASD in
addition to a number of different neuropsychiatric disorders of
variable severity,10 and the same is true of deletions in the
SHANK11 and NRXN genes.12–15 We are unaware of any susceptibility gene/locus that shows speciﬁcity for a single neurodevelopmental disorder.
Such variable expression and pleiotropy (multiple effects of a
single gene) are not unusual, perhaps reﬂecting expression in
different tissues, or shared pathophysiological mechanisms
between disorders.7, 16 The ultimate phenotype may be inﬂuenced by the interplay of these with other factors:genetic
(including sex), environmental (including maternal and hormonal
inﬂuences) and epigenetic.7 A more striking observation is that
some variants, classiﬁed as pathogenic, can be present without
any apparent clinical consequence in some people—i.e., nonpenetrant. In particular, some individuals with ASD or other
neurodevelopmental disorders have been reported to share an
ostensibly pathogenic variant with a phenotypically normal
transmitting parent, and sometimes also one or more unaffected
siblings.17–19 The underlying mechanism illustrated by such cases
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is poorly understood, although factors such as genomic context,
impact on protein structure and function, and the effect of
modiﬁer genes may be important.7
Family based research does indicate that ASD itself is often
expressed as a broader phenotype, beyond the bounds of the
clinical spectrum, with family members often displaying mild,
subclinical, traits.20 Indeed, the sibling recurrence for this broad
autism phenotype is higher than for ASD.21 These milder traits do
not often impact function, and, therefore, may not be immediately
apparent or come to the attention of clinical services, but their
importance lies in their implication for our understanding of the
biology of ASD, and the penetrance and expression of the
underlying genes.
We performed extensive genetic analyses including wholegenome sequencing in an individual with ASD and his family. We
identiﬁed CNV deletions involving NRXN1 and MBD5 in the
proband, but also in his father and sister, neither of whom had
evidence of any clinically overt brain-related phenotype. NRXN1
and MBD5 are implicated in ASD, ID, and other neuropsychiatric
disorders,12, 13, 22, 23 and functional mutations of either gene
might be expected to have phenotypic consequences. We noted
other variants of potential relevance to the ASD phenotype. This
family illustrates that mutations anticipated to be highly penetrant
may in fact be less so, and at times, apparently without
phenotypic consequence.
RESULTS
Clinical characteristics of family
The proband (003) (Fig. 1) was diagnosed with attention deﬁcit
hyperactivity disorder (ADHD) at age 3 years and with ASD at age
5 years through a specialty ASD clinic. His mother and father were
aged 33 and 34 years, respectively, at the time of his conception,
and the mother reported a medically uneventful pregnancy. She
had no history of miscarriage, and the male proband, her ﬁrstborn,
was born by vaginal delivery following spontaneous labor at
39 weeks gestation. Birth weight was 4054 g. There were no
neonatal complications, and no craniofacial dysmorphology
noted. Development during the 1st year was normal, but by
36 months he began losing acquired language, and speech
became echolalic and scripted. Although gross motor control was
intact, ﬁne motor was an additional area of early developmental
difﬁculty. By 36 months, repetitive motor mannerisms and
preoccupations become prominent. Assessment of intellectual
ability and adaptive functioning were consistent with a diagnosis
of intellectual disability, and in the specialty clinic an additional
diagnosis of ADHD was made (Table 1). Further assessment in the
clinic at the age of 5 years identiﬁed more signiﬁcant sociocommunicative vulnerabilities, and a diagnosis of ASD was given.
At that time an Intelligence Quotient (IQ) of 53 was recorded
(verbal IQ = 56, non-verbal IQ = 65), and his adaptive skills were
largely consistent with function in the mildly impaired range
(adaptive composite = 63). At age 12 years 10 months his head
circumference was 57.9 cm, consistent with macrocephaly.
The proband’s younger sister (004) was born following an
uneventful pregnancy by normal vaginal delivery. Birth weight
was 3856 g. She required incubation and monitoring for transient
tachypnea, which resolved spontaneously, but otherwise there
were no perinatal complications. Her early language and motor
milestones were attained without delay. She did experience
stuttering at 36 months, but otherwise exhibited no social or
communicative vulnerabilities. Her cognitive function was in the
superior range on the Wechsler Abbreviated Scale of Intelligence
(WASI-II) age 6 years, and she had above average expressive and
receptive language skills. Her scores on the Autism Diagnostic
Interview-Revised (ADI-R) and the Autism Diagnostic Observation
Schedule (ADOS, module 3), both completed when she was aged
npj Genomic Medicine (2017) 17

9 years, did not indicate ASD symptoms. Similarly, neither
children’s communication checklist (CCC)24 nor the child version
of the social responsiveness scale (SRS)25 revealed any such
developmental vulnerabilities.
We evaluated both parents (001 and 002) for the presence of
neurocognitive vulnerabilities and neuropsychiatric diagnoses
(Table 1). Both graduated high school and attained professional
level employment. The SRS was not consistent with any ASD traits
in either parent, although the communication checklist—adult
(CC-A)26 indicated some maternal and paternal communication
vulnerabilities, and father’s score on the Reading the Mind in the
Eyes Test (RMET)27 was below average, suggesting some
impairment in theory of mind abilities. No additional social or
communication vulnerabilities were apparent, and neither parent
had ﬁndings consistent with ASD. Moreover, besides maternal
post-natal depression, both parents denied any neuropsychiatric
history.
Genetic characterization of family
All four family members provided blood for genotyping. We
initially identiﬁed hemizygous microdeletions in the chromosomal
regions 2p16.3 (50,754,487–50,996,179 [hg19]) and 2q23.1
(148,851,175–149,059,335 [hg19])] in both offspring and their
father. By microarray, we estimated the deletion at 2p16.3 to be
~242 kb eliminating exons 6 to 16 of NRXN1 (Fig. 1). The 2q23.1
deletion was ~215 kb in size, eliminating non-coding exons 2 and
3 in the 5’ untranslated region (UTR) of MBD5 (Fig. 1). We validated
both deletions using SYBR-Green based real-time quantitative
PCR. We found no other CNVs deemed clinically signiﬁcant or of
uncertain clinical signiﬁcance according to the American College
of Medical Genetics’ guidelines,28 in any family member.
We undertook whole-genome sequencing of the proband and
both parents using the BGI platform as previously described.29
This validated the NRXN1 and MBD5 deletions. The breakpoints
of the NRXN1 deletion were further mapped to
50,754,222–51,000,379 [hg19] by Sanger sequencing, and visual
inspection of BAM ﬁles mapped the MBD5 breakpoints to
148,843,025- 149,062,962 [hg19], thereby adjusting the size of
the NRXN1 and MBD5 deletions to ~246 and ~220 kb, respectively.
There were no additional structural alterations at the breakpoints.
In the proband and his father we found a missense variant
(c.G418T [p.D140Y]) in NLGN1 (an ASD risk gene), which was
predicted by in silico algorithms to be damaging. Targeted Sanger
sequencing of the unaffected sibling’s DNA did not identify the
variant. Finally, the proband had a de novo 2 bp deletion
(c.461_462del [p.L154fs]) involving ASB14. Although the mutation
was predicted to lead to a frameshift of the protein, this gene has
not been associated with ASD or other neurodevelopmental
disorders, to date. We identiﬁed no other rare loss-of-function or
de novo missense SNVs this family’s genomic sequences.
Prevalence and penetrance of overlapping mutations
We next examined clinical and population data sets to investigate
the penetrance of the putative mutations identiﬁed. For NRXN1
and MBD5, we speciﬁcally focused on CNV deletions with at least a
50% reciprocal overlap with that of the proband (hereafter termed
‘‘overlapping CNVs’’). First, we examined clinical data sets
comprising individuals (N = 19,237, comprising N = 5273 cases
and their family members) ascertained by way of one or more
different neurodevelopmental diagnoses, including ASD,6, 30
developmental delay,31 OCD32 and cerebral palsy (CP).19 These
individuals had been genotyped on a variety of platforms, each
allowing a CNV detection threshold of 10 kb using ﬁve or more
probes. Only CNVs called with two or more algorithms were
considered. Thus, we identiﬁed one clinical case with an
overlapping NRXN1 CNV (chr2: 50,761,808–51,037,134 [hg19]),
and two clinical cases with overlapping MBD5 CNVs (chr2:
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Fig. 1

Pedigree with microarray results and annotated NRXN1 (a) and MBD5 (b) CNVs

148,787,060- 149,106,568 and 148,842,503–149,059,335 [hg19])
from a total of 6 and 7 exon-impacting NRXN1 and MBD5 CNVs,
respectively. All three individuals have developmental delay but
no further phenotype information was available. We next
examined population data sets, comprising samples genotyped

on the Illumina 2.5M platform (KORA and COGEND)33, 34 and
Illumina 1M platform (WTCCC, SAGE, ONC, and HABC),35–37 giving
rise to a total sample size of 13,871. A CNV detection threshold of
30 kb was employed using a minimum of ﬁve probes. We
considered all CNVs called by two or more algorithms, identifying
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Nil
Language 7%ile, pragmatics 9%ile,
social engagement 19%ile
T-score = 43 (normal)

Language 42%ile, pragmatics 7%ile,
social engagement 7%ile
T-score = 61 (normal)
109 (73%ile)
31 (86% correct)

SRS

PPVT

RMET

NA

86 (9%ile, aged 7:4)

NA

73 (86%ile, aged 3:7)

T score = 45 (normal)

GCC = 71 (32%ile)

Standard score = 50 (<0.1%ile)
CCC: GCC = 30 (1%ile)
NA

CCC:

Nil

HC = 51 cm, height = 106.7 cm,
weight = 17.7 kg (age 6:6)

NA

NVIQ = 112

VIQ = 124,

FSIQ = 121,

None
WASI

Targeted Sanger: NLGN1 +/+

NRXN1 del[pat]/+ MBD5 del
[pat]/+

−004
Female

OWLS:

Nil

HC = 57.9 cm, height = 166.5 cm,
weight = 58.1 kg (age 12:10)

Comm 3%ile, daily 1%ile, social
<1%ile

NVIQ = 65

VIQ = 56,

FSIQ = 53,

ASD, ID, ADHD
WPPSI-IIIF

ASB14, c.461 462del [p.L154fs]
NLGN1, c.G418T [p.D140Y]

NRXN1 del[pat]/+ MBD5
del[pat]/+

−003
Male

NA not available, CC-A communication checklist–adult, CCC children's communication checklist, OWLS oral and written language scales, SRS social responsiveness scale, PPVT Peabody Picture Vocabulary Test,
RMET Reading the Mind in the Eyes Test, FSIQ fullscale IQ, VIQ verbal IQ, NVIQ nonverbal IQ

19 (53% correct)

101 (%ile)

CC-A:

Nil

HC = 58 cm, height = 182.9 cm,
weight = 83.9 kg (age 44 years)

CC-A:

Language

Medical

–

–

HC = 56 cm, height = 166.4 cm,
weight = 60.3 kg (age 45 years)

–

–

Morphology (HC = head circumference)

–

–

NA

None
NA

None
NA

Clinical diagnosis
IQ

NA

NLGN1, c.G418T [p.D140Y]

–

WGS

Vineland adaptive behavior scales (comm =
communication, daily = daily living)

NRXN1 del/+ MBD5 del/+

NRXN1 +/+ MBD5 +/+

Microarray

−002
Male

−001
Female

Summary of family’s genotypes and phenotypes

Sex

Table 1.
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Fig. 2 CNVs overlapping the family’s NRXN1 (a) and MBD5 (b) CNV deletion from clinical (‘‘clinical’’) and population (‘‘controls’’) data sets, and
DECIPHER and ClinGen

from this pooled data set one NRXN1 CNV and one MBD5 CNV
from a total of 61 (six exonic) and 19 (seven exonic) NRXN1 and
MBD5 CNV deletions, respectively. Consequently, there was no
statistical evidence for a greater prevalence of overlapping NRXN1
or MBD5 CNVs among cases than among controls.

We also considered overlapping CNVs recorded in DECIPHER—a
clinician-submitted sample of 21,688 individuals with identiﬁed
phenotypes and validated CNVs.8 Of this sample, eight individuals
had overlapping NRXN1 CNVs, and one an overlapping MBD5 CNV
(Fig. 2). Similarly, the International Standards for Cytogenetic
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Arrays (ISCA) clinical database38 included 11 overlapping NRXN1
CNVs and 8 overlapping MBD5 CNVs. The phenotypes described
among these 19 individuals all included ID with an additional
diagnosis of ASD in ﬁve. Among these CNVs, DECIPHER inheritance
pattern is described as de novo for the one MBD5 deletion, and
variable for the NRXN1 deletions (de novo for 3, inherited for 3,
and unknown for 2).
We also examined our whole-genome sequenced ASD families
(comprising N = 5205 probands, siblings and parents, see methods) for any additional individuals with damaging NLGN1 variants.
We found overlapping variants in three individuals, two of with
ASD, and one an unaffected father. Exome Aggregation Consortium (ExAC),39 a data set which spans 60,706 unrelated
individuals sequenced as part of various disease-speciﬁc and
population genetic studies, lists two individuals with an overlapping mutation.
DISCUSSION
In the family described here, CNV deletions in two ASD-implicated
genes, NRXN1 and MBD5, are shared by an ASD proband, his
typically developing sibling, and their unaffected father. Based on
extensive literature,40 our clinical diagnostic laboratory would
have assigned either one of these CNVs as ‘‘likely pathogenic’’ for
ASD. In addition, WGS identiﬁed a missense variant in the putative
ASD gene NLGN1 that was paternally transmitted to only the
proband. This is of interest for the known interaction between the
NLGN1 and NRXN1 proteins,41 and in this family the missense
mutation was predicted to be damaging. A de novo frameshift
variant in ASB14 was also identiﬁed in the proband, and although
not brain expressed, we cannot rule out an etiological role for this
mutation.
NRXN1 is one of three neurexin scaffolding proteins; aberrations
in its gene are strongly associated with cognitive, neurodevelopmental and neuropsychiatric phenotypes.12, 13 Deletions in NRXN1
are relatively common in ASD (0.45%) and ID (0.12%) cohorts,12
but much less frequently seen in population based surveys
(~0.02%) (ref. 12). Other studies have also highlighted the fact that
deletions can occur in apparently healthy individuals (ref. 12 and
references therein). An estimate of penetrance for all CNVs for
schizophrenia and neurodevelopmental phenotypes for NRXN1 is
33% (ref. 42). The ExAC constraint metric for this gene is −0.13 (ref.
39), which is consistent with tolerance to copy number variation.
However, its low burden of mutations in the healthy population
coupled with high expression levels (messenger RNA and protein)
results in its categorization as critical to brain development.43
MBD5 encodes a methylated-DNA binding protein, which has
previously been described in the literature as highly penetrant,
characterized in all cases by intellectual disability, ASD and, more
variably, craniofacial abnormalities.22, 23 Most of the cases
described so far have been de novo, although transmission is
sometimes unknown. In the present family, the proband’s
phenotype is largely consistent with previous descriptions
connected with mutations of NRXN1 and MBD5,12, 13, 22, 23
characterized by moderate ID and ASD in the absence of
dysmorphism. The ExAC constraint measure for MBD5 is 0.69
(ref. 39) indicating some degree of intolerance to variation,
although it is not classiﬁed critical to brain development.43
Beyond the gene per se, the exact genomic location of a CNV
may be important in the determination of functional aberration
and phenotypic consequence. In this family, the 2p16.3 deletion
impacted exons 6–16, and our analysis indicated that overlapping
CNVs were rare among clinical cases or population controls.
Crucially, overlapping CNVs were not enriched among the cases
compared with controls. We speculate that this hemizygous
deletion impacting only exons 6–16 may be less penetrant than
others reported for this gene. Indeed, most clinical cases seem to
cluster around exons 1–4 at the 5’ end of the gene, with deletions
npj Genomic Medicine (2017) 17

that impact the subsequent exons showing evidence of lower
penetrance.13 This may be due to inﬂuence of the lncRNA
AK127244 adjacent to the promotor of alpha-NRXN1.13 Confounding the argument of lower penetrance, however, is the 20
individuals with overlapping CNVs in ISCA, DECIPHER, and the
other clinical data sets we examined with variable but largely
overlapping phenotypes.
Similarly, overlapping MBD5 deletions were not enriched
among clinical cases, although mutations described largely
overlap with that of our patient, impacting one or more exons
in the 5’-UTR. Two additional individuals in our clinical data set,
with developmental delay, had identical MBD5 CNVs. Although
these exons are not translated, all 5’-UTR deletions result in
haploinsufﬁciency, with peripheral expression of MBD5 approximately halved.23 Many cases described, including the one in
DECIPHER, have de novo mutations.
Finally, NLGN1, is of potential interest, forming complexes with
NRXN1, and implicated in both structural integrity and function of
synapses.44 While the function of NLGN1 has been well described,
particularly in the context of its interaction with NRXN1, the
phenotype associated with gene mutations has not been
elaborated. One genome-wide CNV analysis of ASD cases
identiﬁed enrichment for CNVs in NLGN1 compared with
population controls,45 and another provided evidence of association between common variants in NLGN1 and schizophrenia in the
Han Chinese population.46 However, the penetrance of the
mutation described in our family is unclear in light of the
identiﬁcation of a similar number of cases in our clinical data set
and ExAC.
Complexity of the etiology underlying ASD is well demonstrated
in families like that presented here, where the most advanced
genomic technologies have provided a comprehensive genetic
proﬁle, and the variants detected are shared among family
members with and without ASD. We are reminded to acknowledge what remains unknown (e.g., the role of environmental
factors and epigenetic regulation) and not to overstate the causal
impact of variants. We are spurred to investigate the mechanisms
whereby genotype can lead to phenotype in some, but not
others.47 Variously, this may be a function of the type of variant
(i.e., loss-of-function, missense, deletion), its location (i.e., exonic,
intronic, regulatory region, intergenic), or the resultant transcript/
isoform.9 We must, however, move from a genetic to a genomic
perspective, recognizing that no gene or gene product functions
in isolation. Indeed, each of the three genetic aberrations in this
family might have been deemed sufﬁcient to explain ASD in the
proband, but all were non-penetrant in other family members. For
future investigations related to penetrance, we recommend the
approach of comparing only highly overlapping CNVs, rather than
all CNVs involving the same gene. A true estimate of penetrance
will require a more robust approach than ours, with access to
comprehensive control data from pedigrees48 and large data
sets.49 For example, although many variants may be very rare in
the population, those that are inherited can be tracked through
family members and their segregation with disease phenotype
examined. This allows a quantiﬁcation of their pathogenicity to be
determined,48 as well as a Bayesian Factor to be estimated, which
can be used as a test of the hypothesis of causality by examining
its distribution under the hypothesis of neutrality.50 Although not
a direct measurement of penetrance per se, this approach does go
some way to quantifying the probability of disease in association
with particular mutations.
Context is crucial. The impact of the wider genomic landscape,
including the epigenome, along with factors such as age, sex and
the early environmental milieu, will undoubtedly contribute to a
person’s evolving phenotypes. The rich tapestry of protein
interactions at the cellular level translate more proximally into
endophenotypes, which, rather than global diagnostic ﬁelds, are
the more internal phenotypic elements or markers revealed by

Published in partnership with the Center of Excellence in Genomic Medicine Research

Variable phenotype in NRXN1, MBD5 and NLGN1
M Woodbury-Smith et al.

7
speciﬁc measures. In the family presented here, the father’s
vulnerabilities decoding emotions from facial stimuli may, for
example, represent such an endophenotype. The ‘‘vulnerable
brain’’ may be impacted by another factor to result in the full
expression of a clinical phenotype. These mechanisms will
become untangled as a result of large, epidemiological studies,
but also the accumulation of evidence from case studies such as
this one.
METHODS
The family described was recruited as part of ongoing studies of the
genetics of ASD (www.mss.ng).51 This data set currently comprises ~2500
probands with ASD and, in most cases, both parents. ASD diagnoses are
made by expert clinicians using the ADI-R and the ADOS combined with
clinical judgment. Probands and their available ﬁrst degree relatives have
all undergone phenotyping as described below, and have provided DNA
for the identiﬁcation of CNVs and SNVs (see below). All data were collected
following informed consent from participants or substitute decision
makers, and the study is conducted with approval from respective local
research ethics boards. The family described in detail in this paper has
provided speciﬁc written consent for their data to be shared in the
scientiﬁc literature in the form of this case report.

Phenotypes
In addition to the ADI-R and ADOS-G, the proband underwent a cognitive
assessment using the Wechsler Preschool and Primary Scale of Intelligence
(WPPSI) and a language assessment with the oral and written language
scales (OWLS-II). Additionally, measures of the proband’s adaptive
functioning (Vineland Adaptive Behavior Scales-II) was completed with
his parents. Both parents were assessed using the Peabody Picture
Vocabulary Test and the RMET (a measure of theory of mind).27 In addition,
both parents completed the CC-A26 and the SRS.25 The proband’s sibling
underwent assessment with the WASI-II, the ADI and the ADOS. Her
parents completed a measure of her social communication (CCC).24 Height,
weight, and head circumference were measured for each family member.

whole-genome sequencing project, are also available in the MSSNG
database on Google Genomics (for access see http://www.mss.ng/
researchers).
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and iPattern. Only CNVs with ﬁve probes or more on the array were called,
with a minimum length cutoff of 30 kb. CNVs were ﬁltered to prioritize rare
variants that occurred with a frequency of<0.1% in control samples (N =
9611). For the purpose of ﬁltering, CNVs with >50% reciprocal overlap were
deemed overlapping. We also removed all CNVs that had >70% overlap
with a known segmental duplication. We further restricted our list to those
with more than 75% overlap with copy number stable regions, according
the stringent CNV map of the human genome.55 All CNVs described in the
index family have been validated using the SYBR green based quantitative
PCR method. The genomic coordinates presented in this paper are based
on the February 2009 Human Genome Build (GRCh37/hg19).
The proband and both parents also underwent whole-genome
sequencing (WGS) by BGI as described previously.29 All identiﬁed variants
were subsequently validated by Sanger sequencing. In addition, the
unaffected sibling underwent targeted Sanger sequencing. We annotated
the Identiﬁed SNVs, and prioritized those likely to be damaging using a
ﬁltering algorithm. This captured all those SNVs that were rare (≤1% minor
allele frequency), and involved loss of function (nonsense, splice site, and
frameshift), and damaging de novo missense mutations (damaging as
evidenced by two of the following criteria: SIFT ≤ 0.05, Polyphen2 ≥ 0.95,
CADD ≥ 15, Mutation Assessor score ≥ 2, placental mammal PhyloP ≥ 2.4
and vertebrate PhyloP ≥ 4).29
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